[ADHD in adulthood--guidelines based on expert consensus with DGPPN support].
Ebert
D
D
Krause
J
J
Roth-Sackenheim
C
C
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D009538:Nicotine / Q000009:adverse effects / Q000627:therapeutic use; D010348:Patient Care Team; D010649:Phenylalanine / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011978:Receptors, Nicotinic / Q000187:drug effects; D012017:Referral and Consultation
D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants; D011978:Receptors, Nicotinic; D016651:Lithium Carbonate; D010649:Phenylalanine; D009538:Nicotine